<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36135988</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-1878</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>BioEssays : news and reviews in molecular, cellular and developmental biology</Title><ISOAbbreviation>Bioessays</ISOAbbreviation></Journal><ArticleTitle>Tubulin deacetylase NDST3 modulates lysosomal acidification: Implications in neurological diseases.</ArticleTitle><Pagination><StartPage>e2200110</StartPage><MedlinePgn>e2200110</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/bies.202200110</ELocationID><Abstract><AbstractText>Neurological diseases (NDs), featured by progressive dysfunctions of the nervous system, have become a growing burden for the aging populations. N-Deacetylase and N-sulfotransferase 3 (NDST3) is known to catalyze deacetylation and N-sulfation on disaccharide substrates. Recently, NDST3 is identified as a novel deacetylase for tubulin, and its newly recognized role in modulating microtubule acetylation and lysosomal acidification provides fresh insights into ND therapeutic approaches using NDST3 as a target. Microtubule acetylation and lysosomal acidification have been reported to be critical for activities in neurons, implying that the regulators of these two biological processes, such as the previously known microtubule deacetylases, histone deacetylase 6 (HDAC6) and sirtuin 2 (SIRT2), could play important roles in various NDs. Aberrant NDST3 expression or tubulin acetylation has been observed in an increasing number of NDs, including amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD), schizophrenia and bipolar disorder, Alzheimer's disease (AD), and Parkinson's disease (PD), suggesting that NDST3 is a key player in the pathogenesis of NDs and may serve as a target for development of new treatment of NDs.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiangning</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiou</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9115-8708</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS074324</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS089616</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS110098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS128494</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bioessays</MedlineTA><NlmUniqueID>8510851</NlmUniqueID><ISSNLinking>0265-9247</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.-</RegistryNumber><NameOfSubstance UI="D056565">Sirtuin 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.8.2.-</RegistryNumber><NameOfSubstance UI="D015238">Sulfotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014404">Tubulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="N">Disaccharides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056565" MajorTopicYN="N">Sirtuin 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015238" MajorTopicYN="N">Sulfotransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014404" MajorTopicYN="N">Tubulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease (AD)</Keyword><Keyword MajorTopicYN="N">NDST3</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD)</Keyword><Keyword MajorTopicYN="N">lysosomal acidification</Keyword><Keyword MajorTopicYN="N">lysosomal storage disorder</Keyword><Keyword MajorTopicYN="N">microtubule acetylation</Keyword><Keyword MajorTopicYN="N">neurological diseases</Keyword></KeywordList><CoiStatement>CONFLICT OF INTEREST. The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>10</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36135988</ArticleId><ArticleId IdType="mid">NIHMS1846911</ArticleId><ArticleId IdType="pmc">PMC9829454</ArticleId><ArticleId IdType="doi">10.1002/bies.202200110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, Culpepper WJ, Dorsey ER, Elbaz A, Ellenbogen RG, Fisher JL, Fitzmaurice C, Giussani G, Glennie L, James SL, Johnson CO, Kassebaum NJ, Logroscino G, Marin B, &#x2026; Vos T (2019). Global, regional, and national burden of neurological disorders, 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(5), 459&#x2013;480. 10.1016/S1474-4422(18)30499-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30499-X</ArticleId><ArticleId IdType="pmc">PMC6459001</ArticleId><ArticleId IdType="pubmed">30879893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, &amp; Bohr VA (2019). Ageing as a risk factor for neurodegenerative disease. Nature Reviews Neurology, 15(10), 565&#x2013;581. 10.1038/s41582-019-0244-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0244-7</ArticleId><ArticleId IdType="pubmed">31501588</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, Periz G, Lu YN, Tang Q, Liu Y, Zhang T, Shah Y, Thombre R, Aljumaah R, Li W, Mojsilovic-Petrovic J, Ji Y, Johnson K, Kalb R, &amp; Wang J (2019). L3MBTL1 regulates ALS/FTD-associated proteotoxicity and quality control. Nature Neuroscience, 22(6), 875&#x2013;886. 10.1038/s41593-019-0384-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0384-5</ArticleId><ArticleId IdType="pmc">PMC6588399</ArticleId><ArticleId IdType="pubmed">31061493</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkbeiner S (2020). The autophagy lysosomal pathway and neurodegeneration. Cold Spring Harbor Perspectives in Biology, 12(3), a033993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773515</ArticleId><ArticleId IdType="pubmed">30936119</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardana R, &amp; Emr SD (2021). Membrane Protein Quality Control Mechanisms in the Endo-Lysosome System. Trends in Cell Biology, 31(4), 269&#x2013;283. 10.1016/j.tcb.2020.11.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2020.11.011</ArticleId><ArticleId IdType="pubmed">33414051</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Liu M, Liu Y, Hwang R, Zhang T, &amp; Wang J (2021). NDST3 deacetylates &#x3b1;&#x2010;tubulin and suppresses V&#x2010;ATPase assembly and lysosomal acidification. The EMBO Journal, 40, e107204. 10.15252/embj.2020107204</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020107204</ArticleId><ArticleId IdType="pmc">PMC8488563</ArticleId><ArticleId IdType="pubmed">34435379</ArticleId></ArticleIdList></Reference><Reference><Citation>Roll-Mecak A (2020). The Tubulin Code in Microtubule Dynamics and Information Encoding. Developmental Cell, 54(1), 7&#x2013;20. 10.1016/j.devcel.2020.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2020.06.008</ArticleId><ArticleId IdType="pubmed">32634400</ArticleId></ArticleIdList></Reference><Reference><Citation>Janke C, &amp; Montagnac G (2017). Causes and Consequences of Microtubule Acetylation. Current Biology, 27(23), R1287&#x2013;R1292. 10.1016/j.cub.2017.10.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2017.10.044</ArticleId><ArticleId IdType="pubmed">29207274</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchisella F, Coffey ET, &amp; Hollos P (2016). Microtubule and microtubule associated protein anomalies in psychiatric disease. Cytoskeleton, 73(10), 596&#x2013;611. 10.1002/cm.21300</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cm.21300</ArticleId><ArticleId IdType="pubmed">27112918</ArticleId></ArticleIdList></Reference><Reference><Citation>Portran D, Schaedel L, Xu Z, Th&#xe9;ry M, &amp; Nachury MV (2017). Tubulin acetylation protects long-lived microtubules against mechanical ageing. Nature Cell Biology, 19(4), 391&#x2013;398. 10.1038/ncb3481</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb3481</ArticleId><ArticleId IdType="pmc">PMC5376231</ArticleId><ArticleId IdType="pubmed">28250419</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelletti G, Calogero AM, &amp; Rolando C (2021). Microtubule acetylation: A reading key to neural physiology and degeneration. Neuroscience Letters, 755, 135900. 10.1016/j.neulet.2021.135900</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135900</ArticleId><ArticleId IdType="pubmed">33878428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatica D, Lahiri V, &amp; Klionsky DJ (2018). Cargo recognition and degradation by selective autophagy. Nature Cell Biology, 20(3), 233&#x2013;242. 10.1038/s41556-018-0037-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0037-z</ArticleId><ArticleId IdType="pmc">PMC6028034</ArticleId><ArticleId IdType="pubmed">29476151</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, &amp; Wang X (2021). Lysosome biogenesis: Regulation and functions. Journal of Cell Biology, 220(6), e202102001. 10.1083/jcb.202102001</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.202102001</ArticleId><ArticleId IdType="pmc">PMC8105738</ArticleId><ArticleId IdType="pubmed">33950241</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q, Meng B, Xu H, &amp; Mao Z (2020). The emerging roles of vacuolar-type ATPase-dependent Lysosomal acidification in neurodegenerative diseases. Translational Neurodegeneration, 9, 17. 10.1186/s40035-020-00196-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00196-0</ArticleId><ArticleId IdType="pmc">PMC7212675</ArticleId><ArticleId IdType="pubmed">32393395</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh JY, Kim HN, Hwang JJ, Kim YH, &amp; Park SE (2019). Lysosomal dysfunction in proteinopathic neurodegenerative disorders: Possible therapeutic roles of cAMP and zinc. Molecular Brain, 12, 18. 10.1186/s13041-019-0439-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-019-0439-2</ArticleId><ArticleId IdType="pmc">PMC6417073</ArticleId><ArticleId IdType="pubmed">30866990</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobe K, Ledin J, Ringvall M, Holmborn K, Forsberg E, Esko JD, &amp; Kjelle L (2002). Heparan sulfate and development: differential roles of the N-acetylglucosamine N-deacetylase/N-sulfotransferase isozymes. Biochimica et Biophysica Acta (BBA)-General Subjects, 1573(3), 209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417402</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa J-I (2002). Heparan Sulfate/Heparin N-Deacetylase/ N-Sulfotransferase-3 and -4 BT - Handbook of Glycosyltransferases and Related Genes (Taniguchi N, Honke K, Fukuda M, Clausen H, Furukawa K, Hart GW, Kannagi R, Kawasaki T, Kinoshita T, Muramatsu T, Saito M, Shaper JH, Sugahara K, Tabak LA, Van den Eijnden DH, Yanagishita M, Dennis JW, Furukawa K, Hirabayashi Y, &#x2026; Yamashita K (eds.); pp. 496&#x2013;500). Springer; Japan. 10.1007/978-4-431-67877-9_72</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-4-431-67877-9_72</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolls MM, Thyagarajan P, &amp; Feng C (2021). Microtubule dynamics in healthy and injured neurons. Developmental Neurobiology, 81(3), 321&#x2013;332. 10.1002/dneu.22746</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.22746</ArticleId><ArticleId IdType="pmc">PMC7572564</ArticleId><ArticleId IdType="pubmed">32291942</ArticleId></ArticleIdList></Reference><Reference><Citation>Sferra A, Nicita F, &amp; Bertini E (2020). Microtubule dysfunction: A common feature of neurodegenerative diseases. International Journal of Molecular Sciences, 21(19), 7354. 10.3390/ijms21197354</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21197354</ArticleId><ArticleId IdType="pmc">PMC7582320</ArticleId><ArticleId IdType="pubmed">33027950</ArticleId></ArticleIdList></Reference><Reference><Citation>Boiarska Z, &amp; Passarella D (2021). Microtubule-targeting agents and neurodegeneration. Drug Discovery Today, 26(2), 604&#x2013;615. 10.1016/j.drudis.2020.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2020.11.033</ArticleId><ArticleId IdType="pubmed">33279455</ArticleId></ArticleIdList></Reference><Reference><Citation>Janke C, &amp; Magiera MM (2020). The tubulin code and its role in controlling microtubule properties and functions. Nature Reviews Molecular Cell Biology, 21, 307&#x2013;326. 10.1038/s41580-020-0214-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-020-0214-3</ArticleId><ArticleId IdType="pubmed">32107477</ArticleId></ArticleIdList></Reference><Reference><Citation>Moutin MJ, Bosc C, Peris L, &amp; Andrieux A (2021). Tubulin post-translational modifications control neuronal development and functions. Developmental Neurobiology, 81(3), 253&#x2013;272. 10.1002/dneu.22774</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dneu.22774</ArticleId><ArticleId IdType="pmc">PMC8246997</ArticleId><ArticleId IdType="pubmed">33325152</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshun-Wilson L, Zhang R, Portran D, Nachury MV, Toso DB, L&#xf6;hr T, Vendruscolo M, Bonomi M, Fraser JS, &amp; Nogales E (2019). Effects of &#x3b1;-tubulin acetylation on microtubule structure and stability. Proceedings of the National Academy of Sciences, 116(21), 10366&#x2013;10371. 10.1073/pnas.1900441116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1900441116</ArticleId><ArticleId IdType="pmc">PMC6535015</ArticleId><ArticleId IdType="pubmed">31072936</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Schaedel L, Portran D, Aguilar A, Gaillard J, Marinkovich MP, Th&#xe9;ry M, &amp; Nachury MV (2017). Microtubules acquire resistance from mechanical breakage through intralumenal acetylation. Science, 356(6335), 328&#x2013;332. 10.1126/science.aai8764</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aai8764</ArticleId><ArticleId IdType="pmc">PMC5457157</ArticleId><ArticleId IdType="pubmed">28428427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei D, Gao N, Li L, Zhu JX, Diao L, Huang J, Han QJ, Wang S, Xue H, Wang Q, Wu QF, Zhang X, &amp; Bao L (2018). &#x3b1;-Tubulin acetylation restricts axon overbranching by dampening microtubule plus-end dynamics in neurons. Cerebral Cortex, 28(9), 3332&#x2013;3346. 10.1093/cercor/bhx225</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx225</ArticleId><ArticleId IdType="pubmed">28968698</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteves AR, &amp; Cardoso SM (2020). Differential protein expression in diverse brain areas of Parkinson&#x2019;s and Alzheimer&#x2019;s disease patients. Scientific Reports, 10(1), 13149. 10.1038/s41598-020-70174-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-70174-z</ArticleId><ArticleId IdType="pmc">PMC7403590</ArticleId><ArticleId IdType="pubmed">32753661</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi H, Kim HJ, Yang J, Chae S, Lee W, Chung S, Kim J, Choi H, Song H, Lee CK, Jun JH, Lee YJ, Lee K, Kim S, Sim H. ri, Choi Y. Il, Ryu KH, Park JC, Lee D, &#x2026; Mook-Jung I (2020). Acetylation changes tau interactome to degrade tau in Alzheimer&#x2019;s disease animal and organoid models. Aging Cell, 19, e13081. 10.1111/acel.13081</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13081</ArticleId><ArticleId IdType="pmc">PMC6974726</ArticleId><ArticleId IdType="pubmed">31763743</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Sang S, Ren W, Pei Y, Bian Y, Chen Y, &amp; Sun H (2021). Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer&#x2019;s disease: A review (2010&#x2013;2020). European Journal of Medicinal Chemistry, 226, 113874. 10.1016/j.ejmech.2021.113874</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.113874</ArticleId><ArticleId IdType="pubmed">34619465</ArticleId></ArticleIdList></Reference><Reference><Citation>Graziella C, &amp; Daniele C (2019). Acetylation of tubulin: A feasible protective target from neurodevelopment to neurodegeneration. In Neuroprotection in Autism, Schizophrenia and Alzheimer&#x2019;s disease (pp. 273&#x2013;294). Elsevier Inc. 10.1016/B978-0-12-814037-6.00009-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-814037-6.00009-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubey J, Ratnakaran N, &amp; Koushika SP (2015). Neurodegeneration and microtubule dynamics: Death by a thousand cuts. Frontiers in Cellular Neuroscience, 9, 343. 10.3389/fncel.2015.00343</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00343</ArticleId><ArticleId IdType="pmc">PMC4563776</ArticleId><ArticleId IdType="pubmed">26441521</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekooki-Machida Y, &amp; Hagiwara H (2020). Role of tubulin acetylation in cellular functions and diseases. Medical Molecular Morphology, 53(4), 191&#x2013;197. 10.1007/s00795-020-00260-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00795-020-00260-8</ArticleId><ArticleId IdType="pubmed">32632910</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalebic N, Sorrentino S, Perlas E, Bolasco G, Martinez C, &amp; Heppenstall PA (2013). &#x3b1;TAT1 is the major &#x3b1;-tubulin acetyltransferase in mice. Nature Communications, 4, 1962. 10.1038/ncomms2962</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2962</ArticleId><ArticleId IdType="pubmed">23748901</ArticleId></ArticleIdList></Reference><Reference><Citation>North BJ, Marshall BL, Borra MT, Denu JM, &amp; Verdin E (2003). The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Molecular Cell, 11(2), 437&#x2013;444. 10.1016/s1097-2765(03)00038-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1097-2765(03)00038-8</ArticleId><ArticleId IdType="pubmed">12620231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbert C, Guardiola A, &amp; Shao R (2002). HDAC6 is a microtubule-associated deacetylase. Nature, 417, 455&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">12024216</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwood CM, Peppi M, Dryden S, Tainsky MA, &amp; Gow A (2007). Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochemical Research, 32(2), 187&#x2013;195. 10.1007/s11064-006-9127-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9127-6</ArticleId><ArticleId IdType="pubmed">16933150</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerberg L, Hallstr&#xf6;m BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sj&#xf6;stedt E, Lundberg E, Szigyarto CA-K, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, &#x2026; Uhl&#xe9;n M (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Molecular &amp; Cellular Proteomics&#x202f;: MCP, 13(2), 397&#x2013;406. 10.1074/mcp.M113.035600</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M113.035600</ArticleId><ArticleId IdType="pmc">PMC3916642</ArticleId><ArticleId IdType="pubmed">24309898</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa J, &amp; Esko JD (1999). Molecular Cloning and Expression of a Third Member of the Heparan Sulfate/Heparin GlcNAcN-Deacetylase/N-Sulfotransferase Family. Journal of Biological Chemistry, 274(5), 2690&#x2013;2695. 10.1074/jbc.274.5.2690</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.5.2690</ArticleId><ArticleId IdType="pubmed">9915799</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JY, Hwang HG, Lee JY, Kim M, &amp; Kim JY (2020). Cortactin deacetylation by HDAC6 and SIRT2 regulates neuronal migration and dendrite morphogenesis during cerebral cortex development. Molecular Brain, 13, 105. 10.1186/s13041-020-00644-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-020-00644-y</ArticleId><ArticleId IdType="pmc">PMC7382832</ArticleId><ArticleId IdType="pubmed">32711564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalinski AL, Kar AN, Craver J, Tosolini AP, Sleigh JN, Lee SJ, Hawthorne A, Brito-Vargas P, Miller-Randolph S, Passino R, Shi L, Wong VSC, Picci C, Smith DS, Willis DE, Havton LA, Schiavo G, Giger RJ, Langley B, &amp; Twiss JL (2019). Deacetylation of Miro1 by HDAC6 blocks mitochondrial transport and mediates axon growth inhibition. Journal of Cell Biology, 218(6), 1871&#x2013;1890. 10.1083/jcb.201702187</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201702187</ArticleId><ArticleId IdType="pmc">PMC6548128</ArticleId><ArticleId IdType="pubmed">31068376</ArticleId></ArticleIdList></Reference><Reference><Citation>Haigis MC, &amp; Haigis KM (2013). HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. Mol Cancer Res, 11(9), 1072&#x2013;1077. 10.1158/1541-7786.MCR-13-0040-T.HDAC6</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1541-7786.MCR-13-0040-T.HDAC6</ArticleId><ArticleId IdType="pmc">PMC3778089</ArticleId><ArticleId IdType="pubmed">23723075</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Yang X, Li Z, Le W, Hao Y, Song Y, Wang F, &amp; Guan Y (2021). HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy. Neurochemistry International, 149, 105141. 10.1016/j.neuint.2021.105141</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2021.105141</ArticleId><ArticleId IdType="pubmed">34298079</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmigiani RB, Xu WS, Venta-Perez G, Erdjument-Bromage H, Yaneva M, Tempst P, &amp; Marks PA (2008). HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proceedings of the National Academy of Sciences of the United States of America, 105(28), 9633&#x2013;9638. 10.1073/pnas.0803749105</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0803749105</ArticleId><ArticleId IdType="pmc">PMC2443817</ArticleId><ArticleId IdType="pubmed">18606987</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquero A, Scher MB, Lee DH, Sutton A, Cheng H-L, Alt FW, Serrano L, Sternglanz R, &amp; Reinberg D (2006). SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes &amp; Development, 20(10), 1256&#x2013;1261. 10.1101/gad.1412706</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1412706</ArticleId><ArticleId IdType="pmc">PMC1472900</ArticleId><ArticleId IdType="pubmed">16648462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Long X, Ruan X, Wei Q, Zhang L, Wo L, Huang D, Lin L, Wang D, Xia L, Zhao Q, Liu J, Zhao Q, &amp; He M (2021). SIRT2-mediated deacetylation and deubiquitination of C/EBP&#x3b2; prevents ethanol-induced liver injury. Cell Discovery, 7, 93. 10.1038/s41421-021-00326-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00326-6</ArticleId><ArticleId IdType="pmc">PMC8511299</ArticleId><ArticleId IdType="pubmed">34642310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudo N, Ito A, Arata M, Nakata A, &amp; Yoshida M (2018). Identification of a novel small molecule that inhibits deacetylase but not defatty-acylase reaction catalysed by SIRT2. Philosophical Transactions of the Royal Society B: Biological Sciences, 373(1748), 20170070. 10.1098/rstb.2017.0070</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2017.0070</ArticleId><ArticleId IdType="pmc">PMC5915714</ArticleId><ArticleId IdType="pubmed">29685974</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S-H, Ozden O, Liu G, Song HY, Zhu Y, Yan Y, Zou X, Kang H-J, Jiang H, &amp; Principe DR (2016). SIRT2-mediated deacetylation and tetramerization of pyruvate kinase directs glycolysis and tumor growth. Cancer Research, 76(13), 3802&#x2013;3812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930699</ArticleId><ArticleId IdType="pubmed">27197174</ArticleId></ArticleIdList></Reference><Reference><Citation>Suematsu T, Li Y, Kojima H, Nakajima K, Oshimura M, &amp; Inoue T (2014). Deacetylation of the mitotic checkpoint protein BubR1 at lysine 250 by SIRT2 and subsequent effects on BubR1 degradation during the prometaphase/anaphase transition. Biochemical and Biophysical Research Communications, 453(3), 588&#x2013;594. 10.1016/j.bbrc.2014.09.128</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2014.09.128</ArticleId><ArticleId IdType="pubmed">25285631</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake Y, Keusch JJ, Wang L, Saito M, Hess D, Wang X, Melancon BJ, Helquist P, Gut H, &amp; Matthias P (2016). Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nature Chemical Biology, 12(9), 748&#x2013;754. 10.1038/nchembio.2140</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.2140</ArticleId><ArticleId IdType="pubmed">27454931</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas YM, Wu D, Bueler SA, Robinson CV, &amp; Rubinstein JL (2020). Structure of V-ATPase from the mammalian brain. Science, 367(6483), 1240&#x2013;1246. 10.1126/science.aba1120</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1120</ArticleId><ArticleId IdType="pmc">PMC7324285</ArticleId><ArticleId IdType="pubmed">32165585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mijaljica D, Prescott M, &amp; Devenish RJ (2011). V-ATPase engagement in autophagic processes. Autophagy, 7(6), 666&#x2013;668. 10.4161/auto.7.6.15812</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.7.6.15812</ArticleId><ArticleId IdType="pubmed">21494095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, &amp; Nixon RA (2010). Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell, 141(7), 1146&#x2013;1158. 10.1016/j.cell.2010.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.05.008</ArticleId><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Soyombo AA, Tjon-Kon-Sang S, Rbaibi Y, Bashllari E, Bisceglia J, Muallem S, &amp; Kiselyov K (2006). TRP-ML1 Regulates Lysosomal pH and Acidic Lysosomal Lipid Hydrolytic Activity. Journal of Biological Chemistry, 281(11), 7294&#x2013;7301. 10.1074/jbc.M508211200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508211200</ArticleId><ArticleId IdType="pubmed">16361256</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson I, Joosten M, Roberg K, &amp; &#xd6;llinger K (2013). The histone deacetylase inhibitor trichostatin A reduces lysosomal pH and enhances cisplatin-induced apoptosis. Experimental Cell Research, 319(1), 12&#x2013;20. 10.1016/j.yexcr.2012.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yexcr.2012.10.004</ArticleId><ArticleId IdType="pubmed">23063877</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinod V, Padmakrishnan CJ, Vijayan B, &amp; Gopala S (2014). &#x2018;How can I halt thee?&#x2019; The puzzles involved in autophagic inhibition. Pharmacological Research, 82, 1&#x2013;8. 10.1016/j.phrs.2014.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2014.03.005</ArticleId><ArticleId IdType="pubmed">24657238</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng T, Mai S, Roscoe JM, Sheng RR, Ullah M, Zhang J, Katz II, Yu H, Xiong W, &amp; Hu F (2020). Loss of TMEM 106B and PGRN leads to severe lysosomal abnormalities and neurodegeneration in mice. EMBO Reports, 21(10), e50219. 10.15252/embr.202050219</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202050219</ArticleId><ArticleId IdType="pmc">PMC7534636</ArticleId><ArticleId IdType="pubmed">32852886</ArticleId></ArticleIdList></Reference><Reference><Citation>Root J, Merino P, Nuckols A, Johnson M, &amp; Kukar T (2021). Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease, 154, 105360. 10.1016/j.nbd.2021.105360</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105360</ArticleId><ArticleId IdType="pmc">PMC8113138</ArticleId><ArticleId IdType="pubmed">33812000</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtland JL, Bradshaw TWA, Waitt G, Soderblom EJ, Ho T, Rajab A, Vancini R, Kim IH, &amp; Soderling SH (2021). Genetic disruption of washc4 drives endo-lysosomal dysfunction and cognitive-movement impairments in mice and humans. ELife, 10, e61590. 10.7554/eLife.61590</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.61590</ArticleId><ArticleId IdType="pmc">PMC7984842</ArticleId><ArticleId IdType="pubmed">33749590</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe DM, Lee J. hyun, Kumar A, Lee S, Orenstein SJ, &amp; Nixon RA (2013). Autophagy failure in Alzheimer&#x2019;s disease and the role of defective lysosomal acidification. European Journal of Neuroscience, 37(12), 1949&#x2013;1961. 10.1111/ejn.12169</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.12169</ArticleId><ArticleId IdType="pmc">PMC3694736</ArticleId><ArticleId IdType="pubmed">23773064</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA (2020). The aging lysosome: An essential catalyst for late-onset neurodegenerative diseases. Biochimica et Biophysica Acta. Proteins and Proteomics, 1868(9), 140443. 10.1016/j.bbapap.2020.140443</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2020.140443</ArticleId><ArticleId IdType="pmc">PMC7388076</ArticleId><ArticleId IdType="pubmed">32416272</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA (2013). The role of autophagy in neurodegenerative disease. Nature Medicine, 19(8), 983&#x2013;997. 10.1038/nm.3232</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.3232</ArticleId><ArticleId IdType="pubmed">23921753</ArticleId></ArticleIdList></Reference><Reference><Citation>Lencz T, Guha S, Liu C, Rosenfeld J, Mukherjee S, DeRosse P, John M, Cheng L, Zhang C, &amp; Badner JA (2013). Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nature Communications, 4, 2739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3905728</ArticleId><ArticleId IdType="pubmed">24253340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Devenney EM, Strikwerda-Brown C, Hodges JR, Piguet O, &amp; Kiernan MC (2020). Phenotypic variability in ALS-FTD and effect on survival. Neurology, 94(19), e2005&#x2013;e2013. 10.1212/WNL.0000000000009398</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009398</ArticleId><ArticleId IdType="pubmed">32277059</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Alberici A, Cairns NJ, Romano M, &amp; Buratti E (2020). From basic research to the clinic: Innovative therapies for ALS and FTD in the pipeline. Molecular Neurodegeneration, 15, 31. 10.1186/s13024-020-00373-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00373-9</ArticleId><ArticleId IdType="pmc">PMC7268618</ArticleId><ArticleId IdType="pubmed">32487123</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, &amp; Isaacs AM (2018). C9orf72-mediated ALS and FTD: multiple pathways to disease. Nature Reviews Neurology, 14(9), 544&#x2013;558. 10.1038/s41582-018-0047-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens TG, Partridge L, &amp; Isaacs AM (2017). Genetic models of C9orf72: what is toxic? Current Opinion in Genetics and Development, 44, 92&#x2013;101. 10.1016/j.gde.2017.01.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2017.01.006</ArticleId><ArticleId IdType="pubmed">28364657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Jiang J, Gendron TF, McAlonis-Downes M, Jiang L, Taylor A, Garcia SD, Dastidar SG, Rodriguez MJ, &amp; King P (2020). Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nature Neuroscience, 23(5), 615&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384305</ArticleId><ArticleId IdType="pubmed">32284607</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckers J, Tharkeshwar AK, &amp; Van Damme P (2021). C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy, 17(11), 3306&#x2013;3322. 10.1080/15548627.2021.1872189</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2021.1872189</ArticleId><ArticleId IdType="pmc">PMC8632097</ArticleId><ArticleId IdType="pubmed">33632058</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh A, King M, Hamilton J, Pigott T, Elkhatib R, Shah A, &amp; Selek S (2021). Birth Seasonality of Schizophrenia and Bipolar Disorder? A Review of Inpatient Records. Journal of Affective Disorders, 287, 15&#x2013;18. 10.1016/j.jad.2021.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2021.03.002</ArticleId><ArticleId IdType="pubmed">33765537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S, Rajalakshmi AR, Avudaiappan S, &amp; Eswaran S (2021). Exploring the role of macular thickness as a potential early biomarker of neurodegeneration in acute schizophrenia. International Ophthalmology, 41(8), 2737&#x2013;2746. 10.1007/s10792-021-01831-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10792-021-01831-z</ArticleId><ArticleId IdType="pubmed">33856596</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols A, &amp; Lemstra AW (2020). Parkinsonism and Bipolar Disorder. Bipolar Disorders, 22(4), 413&#x2013;415. 10.1111/bdi.12888</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12888</ArticleId><ArticleId IdType="pmc">PMC7317540</ArticleId><ArticleId IdType="pubmed">31954093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Lu W, Wang Z, Ni J, Zhang J, Tang W, &amp; Fang Y (2016). A comprehensive analysis of NDST3 for schizophrenia and bipolar disorder in Han Chinese. Translational Psychiatry, 6, e701. 10.1038/tp.2015.199</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2015.199</ArticleId><ArticleId IdType="pmc">PMC5068873</ArticleId><ArticleId IdType="pubmed">26731438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu L-Z, Jiang T, Cheng Z-H, Zhang Y-C, Ou M-M, Chen M-C, Zhou Z-H, &amp; Ling W-M (2014). rs11098403 polymorphism near NDST3 is associated with a reduced risk of schizophrenia in a Han Chinese population. Neuroscience Letters, 581, 42&#x2013;45. 10.1016/j.neulet.2014.08.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.08.018</ArticleId><ArticleId IdType="pubmed">25139529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Chen J, Li Z, Sun W, Chen B, Li S, Li W, Lu D, Wang Y, &amp; Shi Y (2018). Association study of NDST3 gene for schizophrenia, bipolar disorder, major depressive disorder in the Han Chinese population. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, 177(1), 3&#x2013;9. 10.1002/ajmg.b.32573</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.b.32573</ArticleId><ArticleId IdType="pubmed">29140583</ArticleId></ArticleIdList></Reference><Reference><Citation>Luza S, Opazo CM, Bousman CA, Pantelis C, Bush AI, &amp; Everall IP (2020). The ubiquitin proteasome system and schizophrenia. The Lancet Psychiatry, 7(6), 528&#x2013;537. 10.1016/S2215-0366(19)30520-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(19)30520-6</ArticleId><ArticleId IdType="pubmed">32061320</ArticleId></ArticleIdList></Reference><Reference><Citation>Uranova NA, Bonartsev PD, Androsova LV, Rakhmanova VI, &amp; Kaleda VG (2017). Impaired monocyte activation in schizophrenia: ultrastructural abnormalities and increased IL-1&#x3b2; production. European Archives of Psychiatry and Clinical Neuroscience, 267(5), 417&#x2013;426. 10.1007/s00406-017-0782-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-017-0782-1</ArticleId><ArticleId IdType="pubmed">28314932</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox TM (2020). Lysosomal Diseases and Neuropsychiatry: Opportunities to Rebalance the Mind. Frontiers in Molecular Biosciences, 7, 177. 10.3389/fmolb.2020.00177</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.00177</ArticleId><ArticleId IdType="pmc">PMC7479189</ArticleId><ArticleId IdType="pubmed">33005626</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledano-Zaragoza A, &amp; Ledesma MD (2020). Addressing neurodegeneration in lysosomal storage disorders: Advances in Niemann Pick diseases. Neuropharmacology, 171, 107851. 10.1016/j.neuropharm.2019.107851</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2019.107851</ArticleId><ArticleId IdType="pubmed">31734384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahrens-Nicklas RC, Tecedor L, Hall AF, Lysenko E, Cohen AS, Davidson BL, &amp; Marsh ED (2019). Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder. JCI Insight, 4(21), e131961. 10.1172/jci.insight.131961</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.131961</ArticleId><ArticleId IdType="pmc">PMC6948765</ArticleId><ArticleId IdType="pubmed">31573978</ArticleId></ArticleIdList></Reference><Reference><Citation>Holopainen JM, Saarikoski J, Kinnunen PKJ, &amp; J&#xe4;rvel&#xe4; I (2001). Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). European Journal of Biochemistry, 268(22), 5851&#x2013;5856. 10.1046/j.0014-2956.2001.02530.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0014-2956.2001.02530.x</ArticleId><ArticleId IdType="pubmed">11722572</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesaola F, Quassollo G, Venier AC, De Paul AL, Noher I, &amp; Bisbal M (2021). The neuronal ceroid lipofuscinosis-related protein CLN8 regulates endo-lysosomal dynamics and dendritic morphology. Biology of the Cell, 113(10), 419&#x2013;437. 10.1111/boc.202000016</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/boc.202000016</ArticleId><ArticleId IdType="pubmed">34021618</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach G, Chen CS, &amp; Pagano RE (1999). Elevated lysosomal pH in Mucolipidosis type IV cells. Clinica Chimica Acta; International Journal of Clinical Chemistry, 280(1&#x2013;2), 173&#x2013;179. 10.1016/s0009-8981(98)00183-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0009-8981(98)00183-1</ArticleId><ArticleId IdType="pubmed">10090534</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid JA, Mach L, Paschke E, &amp; Gl&#xf6;ssl J (1999). Accumulation of sialic acid in endocytic compartments interferes with the formation of mature lysosomes. Impaired proteolytic processing of cathepsin B in fibroblasts of patients with lysosomal sialic acid storage disease. Journal of Biological Chemistry, 274(27), 19063&#x2013;19071. 10.1074/jbc.274.27.19063</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.27.19063</ArticleId><ArticleId IdType="pubmed">10383408</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan G, Li D, Zhong X, Liu G, Wang X, Lu Y, Qin F, Guo Y, Duan S, &amp; Li D (2021). Identification of HDAC6 selective inhibitors: pharmacophore based virtual screening, molecular docking and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 39(6), 1928&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pubmed">32178584</ArticleId></ArticleIdList></Reference><Reference><Citation>Nong Y, Hou Y, Pu Y, Li S, &amp; Lan Y (2021). Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors. SLAS Discovery, 26(5), 628&#x2013;641. 10.1177/24725552211002463</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/24725552211002463</ArticleId><ArticleId IdType="pubmed">33783263</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik BR, Maddison DC, Smith GA, &amp; Peters OM (2019). Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Molecular Brain, 12, 100. 10.1186/s13041-019-0504-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-019-0504-x</ArticleId><ArticleId IdType="pmc">PMC6884906</ArticleId><ArticleId IdType="pubmed">31783880</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr ME, &amp; Oddo S (2013). Autophagic/lysosomal dysfunction in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Research and Therapy, 5, 53. 10.1186/alzrt217</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt217</ArticleId><ArticleId IdType="pmc">PMC3979020</ArticleId><ArticleId IdType="pubmed">24171818</ArticleId></ArticleIdList></Reference><Reference><Citation>Aman Y, Schmauck-Medina T, Hansen M, Morimoto RI, Simon AK, Bjedov I, Palikaras K, Simonsen A, Johansen T, Tavernarakis N, Rubinsztein DC, Partridge L, Kroemer G, Labbadia J, &amp; Fang EF (2021). Autophagy in healthy aging and disease. Nature Aging, 1(8), 634&#x2013;650. 10.1038/s43587-021-00098-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-021-00098-4</ArticleId><ArticleId IdType="pmc">PMC8659158</ArticleId><ArticleId IdType="pubmed">34901876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagh MB, Peng S, Chandra G, Zhang Z, Singh SP, Pattabiraman N, Liu A, &amp; Mukherjee AB (2017). Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. Nature Communications, 8, 14612. 10.1038/ncomms14612</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14612</ArticleId><ArticleId IdType="pmc">PMC5344305</ArticleId><ArticleId IdType="pubmed">28266544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-H, Yang D-S, Goulbourne CN, Im E, Stavrides P, Pensalfini A, Chan H, Bouchet-Marquis C, Bleiwas C, Berg MJ, Huo C, Peddy J, Pawlik M, Levy E, Rao M, Staufenbiel M, &amp; Nixon RA (2022). Faulty autolysosome acidification in Alzheimer&#x2019;s disease mouse models induces autophagic build-up of A&#x3b2; in neurons, yielding senile plaques. Nature Neuroscience, 25(6), 688&#x2013;701. 10.1038/s41593-022-01084-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01084-8</ArticleId><ArticleId IdType="pmc">PMC9174056</ArticleId><ArticleId IdType="pubmed">35654956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nah J, Yuan J, &amp; Jung YK (2015). Autophagy in neurodegenerative diseases: From mechanism to therapeutic approach. Molecules and Cells, 38(5), 381&#x2013;389. 10.14348/molcells.2015.0034</Citation><ArticleIdList><ArticleId IdType="doi">10.14348/molcells.2015.0034</ArticleId><ArticleId IdType="pmc">PMC4443278</ArticleId><ArticleId IdType="pubmed">25896254</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Amieva H, Petersen RC, Ch&#xe9;telat G, Holtzman DM, Hyman BT, Nixon RA, &amp; Jones DT (2021). Alzheimer disease. Nature Reviews Disease Primers, 7, 33. 10.1038/s41572-021-00269-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00269-y</ArticleId><ArticleId IdType="pmc">PMC8574196</ArticleId><ArticleId IdType="pubmed">33986301</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Chen F, Zhang M, Chen Y, Cui L, &amp; Liang C (2021). A Review of APOE Genotype-Dependent Autophagic Flux Regulation in Alzheimer&#x2019;s Disease. Journal of Alzheimer&#x2019;s Disease, 84(2), 535&#x2013;555. 10.3233/jad-210602</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-210602</ArticleId><ArticleId IdType="pubmed">34569952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai SSM, Ng KY, Koh RY, Chok KC, &amp; Chye SM (2021). Endosomal&#x2010;lysosomal dysfunctions in Alzheimer&#x2019;s disease: Pathogenesis and therapeutic interventions. Metabolic Brain Disease, 36(6), 1087&#x2013;1100. 10.1007/s11011-021-00737-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11011-021-00737-0</ArticleId><ArticleId IdType="pubmed">33881723</ArticleId></ArticleIdList></Reference><Reference><Citation>Avrahami L, Farfara D, Shaham-Kol M, Vassar R, Frenkel D, &amp; Eldar-Finkelman H (2013). Inhibition of glycogen synthase kinase-3 ameliorates &#x3b2;-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the alzheimer disease mouse model: In vivo and in vitro studies. Journal of Biological Chemistry, 288(2), 1295&#x2013;1306. 10.1074/jbc.M112.409250</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.409250</ArticleId><ArticleId IdType="pmc">PMC3543013</ArticleId><ArticleId IdType="pubmed">23155049</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumenreich S, Barav OB, Jenkins BJ, &amp; Futerman AH (2020). Lysosomal storage disorders shed light on lysosomal dysfunction in Parkinson&#x2019;s disease. International Journal of Molecular Sciences, 21(14), 4966. 10.3390/ijms21144966</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21144966</ArticleId><ArticleId IdType="pmc">PMC7404170</ArticleId><ArticleId IdType="pubmed">32674335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallings RL, Humble SW, Ward ME, &amp; Wade-Martins R (2019). Lysosomal Dysfunction at the Centre of Parkinson&#x2019;s Disease and Frontotemporal Dementia/Amyotrophic Lateral Sclerosis. Trends in Neurosciences, 42(12), 899&#x2013;912. 10.1016/j.tins.2019.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2019.10.002</ArticleId><ArticleId IdType="pmc">PMC6931156</ArticleId><ArticleId IdType="pubmed">31704179</ArticleId></ArticleIdList></Reference><Reference><Citation>van Veen S, Martin S, Van den Haute C, Benoy V, Lyons J, Vanhoutte R, Kahler JP, Decuypere JP, Gelders G, Lambie E, Zielich J, Swinnen JV, Annaert W, Agostinis P, Ghesqui&#xe8;re B, Verhelst S, Baekelandt V, Eggermont J, &amp; Vangheluwe P (2020). ATP13A2 deficiency disrupts lysosomal polyamine export. Nature, 578(7795), 419&#x2013;424. 10.1038/s41586-020-1968-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-1968-7</ArticleId><ArticleId IdType="pubmed">31996848</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh F, &amp; Ganley IG (2021). Parkinson&#x2019;s disease and mitophagy: An emerging role for LRRK2. Biochemical Society Transactions, 49(2), 551&#x2013;562. 10.1042/BST20190236</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20190236</ArticleId><ArticleId IdType="pmc">PMC8106497</ArticleId><ArticleId IdType="pubmed">33769432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wie J, Liu Z, Song H, Tropea TF, Yang L, Wang H, Liang Y, Cang C, Aranda K, Lohmann J, Yang J, Lu B, Chen-Plotkin AS, Luk KC, &amp; Ren D (2021). A growth-factor-activated lysosomal K+ channel regulates Parkinson&#x2019;s pathology. Nature, 592(7855), E10. 10.1038/s41586-021-03438-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03438-x</ArticleId><ArticleId IdType="pubmed">33790472</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco A, &amp; Fraldi A (2020). Protein Aggregation and Dysfunction of Autophagy-Lysosomal Pathway: A Vicious Cycle in Lysosomal Storage Diseases. Frontiers in Molecular Neuroscience, 13, 37. 10.3389/fnmol.2020.00037</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00037</ArticleId><ArticleId IdType="pmc">PMC7079699</ArticleId><ArticleId IdType="pubmed">32218723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun T, Ko HR, Jo DK, Park KW, Cho SW, Kim J, &amp; Ahn JY (2021). Inhibitor of DNA binding 2 (Id2) mediates microtubule polymerization in the brain by regulating &#x3b1;K40 acetylation of &#x3b1;-tubulin. Cell Death Discovery, 7(1), 257. 10.1038/s41420-021-00652-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00652-4</ArticleId><ArticleId IdType="pmc">PMC8455547</ArticleId><ArticleId IdType="pubmed">34548475</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen S, &amp; Kozikowski AP (2020). A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014&#x2013;2019). Expert Opinion on Therapeutic Patents, 30(2), 121&#x2013;136. 10.1080/13543776.2019.1708901</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2019.1708901</ArticleId><ArticleId IdType="pmc">PMC6950832</ArticleId><ArticleId IdType="pubmed">31865813</ArticleId></ArticleIdList></Reference><Reference><Citation>Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, Miller CCJ, Whitworth AJ, &amp; De Vos KJ (2014). Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nature Communications, 5, 5245. 10.1038/ncomms6245</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6245</ArticleId><ArticleId IdType="pmc">PMC4208097</ArticleId><ArticleId IdType="pubmed">25316291</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S, Wei X, Jian W, Qin Y, Liu J, Zhu S, Jiang F, Lou H, &amp; Zhang B (2020). Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson&#x2019;s Disease. Frontiers in Aging Neuroscience, 12, 78. 10.3389/fnagi.2020.00078</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.00078</ArticleId><ArticleId IdType="pmc">PMC7137996</ArticleId><ArticleId IdType="pubmed">32296327</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi T, Maeda R, Terada M, Sato S, Fujii T, Ito M, Hashikami K, Kawamoto T, &amp; Tanaka M (2021). A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer&#x2019;s disease and tauopathy in mice. Scientific Reports, 11, 15423. 10.1038/s41598-021-94923-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-94923-w</ArticleId><ArticleId IdType="pmc">PMC8322070</ArticleId><ArticleId IdType="pubmed">34326423</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteves AR, Palma AM, Gomes R, Santos D, Silva DF, &amp; Cardoso SM (2019). Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer&#x2019;s and Parkinson disease pathology. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1865(8), 2008&#x2013;2023. 10.1016/j.bbadis.2018.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.11.014</ArticleId><ArticleId IdType="pubmed">30572013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Anoopkumar-Dukie S, Arora D, &amp; Davey AK (2020). Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases. European Journal of Pharmacology, 867, 172847. 10.1016/j.ejphar.2019.172847</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2019.172847</ArticleId><ArticleId IdType="pubmed">31812544</ArticleId></ArticleIdList></Reference><Reference><Citation>Picci C, Wong VSC, Costa CJ, McKinnon MC, Goldberg DC, Swift M, Alam NM, Prusky GT, Shen S, Kozikowski AP, Willis DE, &amp; Langley B (2020). HDAC6 inhibition promotes &#x3b1;-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice. Experimental Neurology, 328, 113281. 10.1016/j.expneurol.2020.113281</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113281</ArticleId><ArticleId IdType="pubmed">32147437</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>